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Copy number variant (CNV) analysis was performed on
renal cell carcinoma (RCC) specimens (chromophobe,
clear cell, oncocytoma, papillary type 1, and papillary
type 2) using high-resolution arrays (1.85 million
probes). The RCC samples exhibited diverse genomic
changes within and across tumor types, ranging from
106 to 2238 CNV segments in a clear-cell specimen
and in a papillary type 2 specimen, respectively. De-
spite this heterogeneity, distinct CNV segments were
common within each tumor classification: chromo-
phobe (seven segments), clear cell (three segments),
oncocytoma (nine segments), and papillary type 2
(two segments). Shared segments ranged from a
6.1-kb deletion (oncocytomas) to a 208.3-kb deletion
(chromophobes). Among common tumor type–spe-
cific variations, chromophobes, clear-cell tumors,
and oncocytomas were composed exclusively of non-
coding DNA. No CNV regions were common to papil-
lary type 1 specimens, although there were 12 ampli-
fications and 12 deletions in five of six samples. Three
microRNAs and 12 mRNA genes had a >98% coding
region contained within CNV regions, including mul-
tiple gene families (chromophobe: amylases 1A, 1B,
and 1C; oncocytoma: general transcription factors
2H2, 2B, 2C, and 2D). Gene deletions involved in his-
tone modification and chromatin remodeling affected
individual subtypes (clear cell: SFMBT and SETD2;
papillary type 2: BAZ1A) and the collective RCC group
(KDM4C). The genomic amplifications/deletions
identified herein represent potential diagnostic
and/or prognostic biomarkers. (Am J Pathol 2012, 180:
2427–2439; http://dx.doi.org/10.1016/j.ajpath.2012.01.044)The annual incidence of renal cell carcinoma (RCC) has
increased steadily in the United States for the past three
decades, with approximately 58,000 new cases diag-
nosed in 2010, representing 3% of all malignancies.1,2
Treatment of RCC is complicated by the fact that it is not
a single disease but composes multiple tumor types with
different morphological characteristics, clinical courses,
and outcomes (ie, clear-cell carcinoma, 82% of RCC
cases; type 1 or 2 papillary tumors, 11% of RCC cases;
chromophobe tumors, 5% of RCC cases; and collecting
duct carcinoma, approximately 1% of RCC cases).2,3
Benign renal neoplasms are subdivided into papillary
adenoma, renal oncocytoma, and metanephric ade-
noma.2,3 Treatment of RCC often involves surgical resec-
tion of a large renal tissue component or removal of the
entire affected kidney because of the relatively large size of
renal tumors on discovery and the availability of a life-sus-
taining bilateral organ. Renal tumor classification provides
predominantly postsurgical information pertinent to fol-
low-up treatment (eg, tumor subtypes, such as papillary
type 2, are prone to metastasis, whereas others, such as
oncocytoma, are benign). Molecular assays could help
classify RCC specimens that are difficult to identify using
standard immunohistochemical (IHC) approaches and pro-
vide a basis for evaluation of biopsy specimens or fine-
needle aspirates from kidney tumors before treatment.
The differential diagnosis of renal cancers relies
largely on morphological and IHC analysis of tissue spec-
imens. Recent advances in our understanding of the
genomic basis of RCC have come from molecular anal-
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AJP June 2012, Vol. 180, No. 6ysis of hereditary forms, which account for 2% of renal
cancer cases.4 The most common hereditary renal can-
cers are associated with the following: i) Von Hippel–
Lindau (VHL) syndrome, usually caused by deletions in
the VHL gene on chromosome 3p25-p26, which results in
clear-cell tumors; ii) mutations in the MET proto-onco-
gene on chromosome 7q31, which results in papillary
RCCs; iii) familial renal oncocytomas associated with Birt-
Hogg-Dube (BHD) syndrome and the BHD gene on chro-
mosome 17p11; and iv) hereditary leiomyomatosis and
renal carcinomas with germline mutations in the fumarate
hydratase gene on chromosome 1q42.1.5 In addition to
these hereditary renal cancers, subjects with germline
mutations in succinate dehydrogenase B are predis-
posed to RCC, whereas patients with tuberous sclerosis
complex typically develop renal cancers at a much
younger age than the general population.6,7 Molecular
diagnostic techniques (cytogenetic karyotyping, fluores-
cence in situ hybridization, and array comparative
genomic hybridization), applied to the genes associated
with hereditary forms of RCC, have proved clinically use-
ful for classification of renal tumors. Although sporadic
clear-cell carcinomas typically have VHL mutations con-
sistent with hereditary clear-cell forms, other sporadic
RCCs often lack somatic mutations typical of hereditary
forms, complicating the use of hereditary markers for
classification of these spontaneous renal cancers.
The RCCs, both within and across tumor subclassifica-
tions, exhibit marked molecular heterogeneity, consistent
with the theory that tumorigenesis requires an accumulation
of mutations to undergo neoplastic transformation.8 This
inherent genomic instability among sporadic tumors com-
plicates the identification of diagnostic, tumor type–specific
biomarkers and the search for underlying cancer-causing
mutations. In a recent exome sequencing study, more
than half of 101 renal clear-cell carcinoma cases con-
tained somatic mutations within the VHL gene, which is
an established hallmark of this type of tumor.9 Determi-
nation of robust RCC biomarkers for sporadic RCC will
likely require interrogation of additional genomic se-
quences, including noncoding regions to identify tumor
type–specific changes that can affect gene expression
through modification of chromatin structure and/or alter-
ation of transcriptional regulatory elements, including
promoters, enhancers, activators, and repressors.
Oligonucleotide microarrays designed to interrogate
single-nucleotide polymorphisms (SNPs) have proved
clinically useful as an accessory tool for classification of
challenging renal epithelial tumors, including specimens
that have undergone formalin fixation and preservation in
paraffin.10 Profiling the genome for novel and/or common
genetic lesions was limited in these previous studies by
both fragmentation of the DNA during fixation and the low
density of genomic targets on the arrays (10,000 to
250,000). The current study was designed to evaluate
copy number variations (CNVs) in canonical RCC tumors
using high-mol.wt. DNA (10 kb) from fresh specimens
and high-resolution arrays (1,852,600 distinct targets) to
characterize CNV for direct comparison with our in-house
reference library of normal tissues generated using the
same platform. We characterized five subtypes of renalcancers (chromophobe, clear cell, oncocytoma, and papil-
lary types 1 and 2) for the distribution of CNV both within
and across tumors spanning the entire genome for the
presence of diagnostic biomarkers and rearrangements in-
dicative of underlying mechanisms of tumorigenesis. Com-
mon tumor type–specific patterns of CNV were associated
with four of the five tumor classifications, despite a back-
ground of immense CNV variation within each sample.
Materials and Methods
Tissue Samples
Tissue samples were obtained from the University of
Pittsburgh Health Sciences Tissue Bank using an honest
broker system and according to Institutional Review
Board–approved protocol 970480. Samples were ac-
quired as surgical specimens and flash frozen in a
1.8-mL cryotube (NalgeNunc, Inc., Rochester, NY), fol-
lowed by immediate storage at 80°C. Each tumor sam-
ple (n  27) was classified into one of five renal cancer
subtypes (chromophobe, n  5; clear cell, n  5; onco-
cytoma, n  5; papillary type 1, n  6; papillary type 2,
n  6) by consensus evaluation of correlative H&E-
stained slides performed independently by three anatom-
ical pathologists (S.I.B., A.V.P., R.D.) (Figure 1). Chromo-
phobe tumor cells exhibited a unique microvacuolated
appearance, often with a microvesicular cytoplasmic pat-
tern and prominent cell membranes (Figure 1A). Clear-
cell specimens typically exhibited a clear cytoplasm, with
Figure 1. Tumors with classic morphological characteristics from the five
most common renal cell tumor subtypes were used to establish copy number
profiles for each group: chromophobe (A), clear cell (B), oncocytoma (C),
papillary type 1 (D), papillary type 2 (E), and normal adjacent (F). Specimens
were chosen based on classification consensus by three independent pathol-
ogists (S.I.B., A.V.P., R.D.), combined with clinical outcomes data. Original
magnification, 20.
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of growth (Figure 1B). Oncocytoma tumor cells had a
large granular cytoplasm and formed clusters of small
aggregates and tubules (Figure 1C). Papillary type 1
tumors consisted of small cuboidal cells, often forming a
single line of uniform nuclei covering vascular papillae
(Figure 1D), whereas papillary type 2 specimens contained
pleomorphic nuclei, with prominent nucleoli in large cells
with an eosinophilic cytoplasm (Figure 1E). The three pa-
thologists also confirmed the absence of pathological fea-
tures in adjacent normal renal samples (n  9) (Figure 1F),
and this normal reference group was expanded by inclu-
sion of 14 normal thyroid samples and eight normal lung
specimens. DNA from each of these specimens was ana-
lyzed using genotyping microarrays (SNP 6.0; Affymetrix,
Sunnyvale, CA). Additional papillary type 2 specimens and
matching blood samples were obtained from two patients
for direct comparison of the results obtained by microarray
analysis to whole genome paired-end sequencing per-
formed on the SOLiD 4 system (sequencing by oligonucle-
otide ligation and detection; Life Technologies, Foster City,
CA). The blood samples were collected by the University of
Pittsburgh Health Sciences Tissue Bank in EDTA K2 tubes
(Becton, Dickinson and Company, Franklin Lakes, NJ), fol-
lowed by centrifugation (1500  g for 10 minutes) for sep-
aration of the white blood cell layer. The plasma and buffy
coat were serially collected and immediately stored at
80°C.
DNA Isolation, Hybridization, and Array Processing
Genomic DNA was purified from frozen samples, follow-
ing the DNeasy Blood and Tissue Kit (Qiagen, Valencia,
CA). Briefly, 0.25 mg of frozen tissue was placed in Qia-
gen buffer and proteinase K (600 mAU/mL) and incu-
bated for 3 hours at 150 rpm. After tissue lysis and protein
removal, genomic DNA was eluted in 100 L of Buffer AE
(Qiagen). Only samples with a spectrophotometric ab-
sorption ratio of 260/280  1.8 (Nanodrop ND-1000
spectrophotometer; NanoDrop, Wilmington, DE) were in-
cluded in subsequent assays. Purified genomic DNA was
evaluated using agarose gels (2%) or microfluidic chips
(12,000 DNA Chip, Bioanalyzer 2100; Agilent Technolo-
gies, Santa Clara, CA) to confirm that the DNA from each
specimen had a high mol.wt. (10 kb), with minimal
detectable degradation. Samples were assayed follow-
ing the Affymetrix Genome-Wide Human SNP Array 6.0
protocol (Affymetrix) comprising 1.8 million genetic mark-
ers with a similar distribution of SNPs (906,600) and non-
polymorphic probes (946,000). StyI and NspI restriction
enzymes (New England Biolabs, Ipswich, MA) were used
to separately digest 250 ng of DNA, resulting in a total
digest of 500 ng of whole genomic DNA per sample.
Each sample was ligated with the appropriate adaptor
(Sty or Nsp) provided in the Affymetrix 6.0 protocol, and
a total of seven PCRs were performed per sample (three
StyI and four NspI restriction digest/ligation DNA reac-
tions) and pooled into one tube, with a total volume of 700
L. Purification of the resulting PCR products was per-
formed using the protocol associated with the Affymetrix
Cytogenetics Copy Number Assay, which required theuse of Agencourt AMPure beads (Beckman Coulter, Dan-
vers, MA). Each pooled sample was fragmented with
DNAse1, biotinylated, and end labeled. Samples were
subsequently hybridized on Genome-Wide SNP 6.0 ar-
rays for 18 hours at 50°C with rotation (60 rpm) in an
Affymetrix Gene Chip Hybridization Oven (model 640).
Arrays were washed, stained, and scanned according to
the Affymetrix Genome-Wide SNP 6.0 protocol using the
Affymetrix GeneChip Fluidics Station (model 450), Ge-
neChip Scanner 3000 7G, and GeneChip Command Con-
sole software version 3.0.2 (Affymetrix, Sunnyvale, CA). The
entire study data set has been deposited under accession
number GSE34676 at the Gene Expression Omnibus web-
site (http://www.ncbi.nlm.nih.gov/geo, last accessed De-
cember 22, 2011).
Paired-End Sequencing
DNA was purified from matched patient tumor and blood
specimens using the Qiagen Genomic Tip protocol
(Genomic-tip 100/G). Briefly, cells were lysed and DNA was
bound to anion exchange resin under low salt and pH
conditions. Impurities were eluted, followed by DNA precip-
itation and suspension in low Tris-EDTA (10mmol/L Tris and
0.1 mmol/L EDTA, pH 8.0). Fragment libraries were gener-
ated according to the manufacturer’s instructions (SOLiD 4
System Library Preparation Guide, part 4445673; Applied
Biosystems, Foster City, CA) using the SOLiD Fragment
Library Construction Kit with 2% Size Select E-gels (Invitro-
gen Corp, Carlsbad, CA) and SOLiD Fragment Library Oli-
gos Kit (Applied Biosystems, Carlsbad). Quantification was
performed with the SOLiD Library TaqMan Quantitation Kit
(Invitrogen Corp).
In short, 5 g of genomic DNA from each sample was
sheared to a peak size distribution approximating 150- to
180-bp fragments (Covaris S2; Covaris Inc., Woburn,
MA). The DNA fragments underwent end repair and liga-
tion with double-stranded P1 and P2 adaptors, followed
by size selection using the E-Gel iBase Power System
and the E-Gel Safe Imager Real-time Transilluminator
(Invitrogen Corp). DNA was collected, pooled, and puri-
fied, and sizes were confirmed to be in a range of 200 to
250 bp on the BioAnalyzer 2100 with the DNA 1000 chip
kit (Agilent Technologies). The library was amplified and
nick translated (GeneAmp PCR System 9700; Applied
Biosystems) using the Platinum PCR Amplification Mix
(SOLiD Fragment Library Construction Kit; Life Technol-
ogies). The DNA was purified, and both samples and
quantitative PCR standards were run in triplicate in the
7900HT Fast Real-Time PCR System (Applied Biosys-
tems), including nontemplate controls (40 cycles at 95°C
for 2 minutes, 95°C for 15 seconds, and 60°C for 1 min-
ute), to determine library concentration. Based on the
quantitative PCR results for each library, we used the SOLiD
EZ bead system (Life Technologies) to generate beads with
attached templates following the manufacturer’s protocol
(Quick Reference Cards; Life Technologies). A PCR emul-
sion was generated in the SOLiD EZ bead Emulsifier, fol-
lowed by PCR amplification in the EZ bead PCR Amplifier
using the E80 protocol. Beads were collected in the EZ
Bead Enricher, and the concentration of P2-positive beads
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(Thermo Fisher Scientific Inc., Wilmington, DE).
A work flow analysis was performed on the SOLiD 4
system to determine bead quality and optimal dilution for
whole genome sequencing. Beads were deposited at low
density (20  106 beads). The work flow analysis slide
containing one quadrant with beads was placed on the
flow cell chamber, and a single strip of sequencing liga-
tion enzymes (SOLiD ToP Workflow Analysis Reagents)
was added to the chilling block. Sequencing proceeded
through one ligation to generate a focal map and deter-
mine quality metrics (P2 to P1 ratio and noise to signal
ratio) and median number of P2-positive beads per
panel. Based on the results (noise to signal ratio 6%,
90  P2/P1  100), an entire slide was loaded and
paired-end sequencing was performed by oligonucleo-
tide ligation and detection of clonally amplified DNA frag-
ments linked to beads. Dye-labeled probes were sequen-
tially ligated, interrogating a two-base position at a time.
Images were captured corresponding to unique emission
spectra for each of the four different dyes. Forward se-
quencing covered 50 bp from the P1 adaptor end, and
reverse sequencing covered 35 bp from the P2 adaptor
end, of the DNA template. Images of the 2357 panels in
each of four channels per cycle were saved for analysis.
Data Analysis
The Affymetrix Genotyping Console (version 3.0.2) was
used to generate an SNP call for each probe set on each
array. SNP calls were determined for an average of
96.78% (SD, 4.27%) of the array probe sets per speci-
men throughout the study. Affymetrix CEL and CHP files
were transferred to Partek Genomics Suite version 6.5
(Partek Inc., St Louis, MO) for copy number and loss-of-
heterozygosity (LOH) analysis, respectively. The CEL
files were imported using the default setting, which ad-
justs hybridized intensities based on fragment length and
probe sequence. Copy number was generated by com-
paring the hybridized intensities of each array with the
laboratory normal tissue reference set (n  31), eliminat-
ing interlaboratory variability introduced by comparison
to other databases, such as the HapMap.11 Copy num-
ber measurements were smoothed based on local gua-
nine-cytosine content using a 1-megabase window.12
The Partek segmentation algorithm was used to identify
regions of significant CNV from normal, consisting of a
minimum of 30 genomic markers and P  0.001, with
signal to noise and expected range set to 0.3. The median
length of intermarker spacing on the SNP 6.0 array is 680
bp, with a median length of a 30-marker region approxi-
mately 20 kb. Regions of LOH were identified for tumors
with a matched normal pair (two chromophobe, one clear-
cell, one papillary type 1, and one papillary type 2 sample)
using the Hidden Markov Model in Partek Genomics Suite.
The de novo paired-end papillary type 2 specimens
and blood whole genome sequences were mapped
against the human reference sequence (HG18) using the
Mapping program of Bioscope software version 1.3 (Life
Technologies). These files were entered into the Pairing
program to generate binary sequence alignment mapfiles for tertiary analysis. The binary sequence alignment
map files were interrogated for global and local CNV for
correlation with the array results. A direct comparison of
global and local CNV data for tumor versus blood was
obtained using a Perl script. A text file was generated from
the comparison of the two general feature format files, which
was loaded into Partek for tertiary comparisons.
Results
CNV in RCC Tumor Subclassifications
There were pronounced disparities in the number of CNV
regions identified as statistically different from normal in
each of the tumor samples. For example, only 106 CNV
regions were detected in one clear-cell specimen,
whereas there were 2238 CNV segments in a papillary
type 2 specimen [identification (ID) numbers 513 and
532; Table 1]. This variability was present both within and
across tumor subclassifications. The greatest amount of
global CNV was present in chromophobe tumors, with an
average of 23.5% of the chromophobe genome exhibit-
ing significant copy number differences compared with
normal specimens (Figure 2). In contrast, oncocytomas
had the smallest amount of their genome affected by
copy number changes, with an average of 8.4% of their
genome reflecting significant changes. Clear-cell tumors
had the largest global copy number losses, with an av-
erage of 14.4% of their genome containing deletions,
whereas papillary type 1 tumors had the greatest amount
of genomic copy number gains (ie, 12.3% of the ge-
nome). Papillary type 1 tumors were also the only tumors
to have a larger amount of copy number amplification
than deletion. Detailed information about the number and
length of CNV segments is available in Table 1.
CNV Segments Common to RCC
The segmentation results were evaluated for the pres-
ence of CNV regions shared across all tumor subtypes
but not present in normal specimens. The most common
CNV amplifications in renal cancers were shared in 20
(74%) of 27 tumor samples composing two distinct seg-
ments, including one on chromosome 7 (58798621 to
158819766) and a second within the mitochondrial ge-
nome (MT 10101 to 16150). Reducing the stringency to
commonality within 19 samples yielded five CNV segments
shared within the entire tumor cohort. The most frequently
shared deletions were detected as two segments on chro-
mosome 9 (6685744 to 6703681 and 6714105 to 6733969)
that were deleted in 19 (70%) of 27 tumors. A list is given of
common segments shared among RCC samples with de-
creasing levels of stringency (see Supplemental Table S1 at
http://ajp.amjpathol.org).
CNV Segments Specific to Individual Tumor
Subclassifications
Individual tumor subclassifications were evaluated for the
presence of significant CNV segments common to all
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ples exhibited an overall total of 1440 amplifications
(mean  SD  288  408) and 1607 deletions (mean 
SD  321  181) among the five specimens represented
Table 1. CNVs of the RCC Sample Types
Group ID no.
No. of
amplified
segments
No. of
deleted
segment
Chromophobe 508 174 441
509 1011 532
510 42 128
511 64 139
512 149 367
Mean 288 321
SD 408 181
Clear cell 513 17 89
514 104 155
516 109 288
517 43 163
230 93 103
Mean 73 160
SD 41 79
Oncocytoma 524 73 148
525 81 357
526 74 361
527 81 440
221 49 171
Mean 72 295
SD 13 129
Papillary type 1 528 242 354
529 152 181
531 485 645
222 54 114
223 113 232
224 157 308
Mean 201 306
SD 152 187
Papillary type 2 530 32 113
532 739 1499
226 80 148
227 207 464
228 235 317
229 125 249
Mean 236 465
SD 258 522
Group ANOVA P value 0.45 0.53
Data include amplifications and deletions, percentage of the genome
in each sample. None of the P values (bottom row) obtained by ANOVA fo
of a statistically significant difference.
ANOVA, analysis of variance.
Figure 2. The percentage of the genome affected by CNV for chromophobe
(Chromo.; n  5), clear cell (n  5), oncocytoma (Onco.; n  5), papillary
type (Pap.) 1 (n  6), and Pap. 2 (n  6) subtypes. The total represents the
average of copy number segments obtained within a classification. The error
bars represent the SEM. The X and Y chromosomes were excluded because
of sex imbalance, and the percentages were calculated using 3071.36 mega-
bases as the size of the whole genome. There were no statistically significant
differences among the groups for total, deleted, or amplified segments.in this group (Table 1; Figure 3A). Chromosomes 1, 10,
and 19 had the greatest amount of CNV among chromo-
phobe samples; each sample had CN losses covering
44.8% 49.9% (mean SD) of chromosome 1, a 43.5%
51.9% loss of chromosome 10 and a 31.7% 41.6% loss of
chromosome 19. However, four regions exhibited common,
statistically significant CN deletions in every chromophobe
sample tested: a 38.7-kb region on chromosome 1
(1p21.1), a 26.3-kb region on chromosome 6 (6q14.1), and
two regions on chromosome 10, including a 208.3-kb re-
gion (10p12.33) and a 6.8-kb region (10q22.3) (Figure 4).
Comparing the LOH regions found in the two paired chro-
mophobe samples (ID numbers 509 and 512) with the copy
number regions yielded three additional regions that exhib-
ited events in 100% of the samples. These three regions
include a 15.6-kb region on chromosome 1 (1p36.13), a
30-kb region on chromosome 2 (2p16.3), and a 17-kb re-
gion on chromosome 11 (11p15.1) (Figure 4).
Clear-cell tumor samples had the fewest number of CNV
regions detected among each of the tumor subtypes, with a
total of 366 CN amplifications (mean SD 73  41) and
798 deletions (mean  SD  160  79) (Table 1; Figure
Genome
CN gain
(%)
Genome
CN loss
(%)
Minimum
length
(bases)
Maximum
length
(megabases)
3.88 15.00 4742 34.3
39.91 7.29 4803 16.6
0.24 1.83 6735 21.7
0.49 0.26 4686 2.0
5.42 43.30 6257 47.9
9.99 13.54 5445 24.5
16.87 17.61 975 17.5
0.08 11.28 6894 65.4
3.01 2.55 5845 25.2
9.98 17.27 4246 54.7
0.23 38.02 4686 122.6
0.63 2.78 6975 59.3
2.78 14.38 5729 65.4
4.19 14.59 1246 35.5
0.24 0.68 4782 3.3
1.12 12.83 2935 54.7
0.37 3.35 3110 20.3
0.39 9.61 5401 12.0
0.79 12.62 2908 87.9
0.58 7.82 3827 35.6
0.36 5.53 1177 35.1
16.22 5.40 6453 54.7
16.98 0.72 8103 42.9
24.22 6.91 2935 54.7
1.16 0.47 7360 25.4
3.92 7.94 2929 45.1
11.52 21.43 2957 44.0
12.33 7.14 5123 44.5
8.65 7.67 2447 10.7
0.07 1.21 9971 21.7
13.84 17.68 5196 54.7
7.93 5.83 3122 80.1
6.66 20.05 5616 23.9
15.90 6.43 6943 30.6
5.32 6.38 2494 27.4
8.29 9.60 5557 39.7
5.79 7.47 2715 23.1
0.55 0.96 0.54 0.18
V amplifications and deletions, and smallest and largest CNV segments
ect of cancer subtype on the value in each column indicate the presences
with CN
r the eff3B). Typical variant segments in the clear-cell specimens
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gions encountered throughout the study (Table 1). Clear-
cell samples also exhibited vast differences in genotype
among specimens, despite their common phenotype. For
example, there were as few as two small deletions pres-
ent on the short arm of chromosome 3 in one specimen,
whereas nearly the entire short arm region was deleted in
all four of the other specimens (Figure 5). Chromosomes
6, 3, and 10 contained the greatest amount of CNV
among clear-cell samples; each sample had CN losses
covering 40.4%  54.1% of chromosome 6, 35.8% 
23.9% of chromosome 3, and 34.1%  47.4% of chro-
mosome 10 (Figure 3B). There were three common CN
deletion regions on chromosome 3 in every clear-cell
sample, consisting of a 12.5-kb region in 3p26.1, a
57.1-kb region in 3p23, and a 13.7-kb region in 3p21.1
(Figure 5).
Oncocytoma specimens had a total of 358 CN ampli-
fications and an average mean  SD  72  13 is
comparable to clear-cell specimens (Table 1; Figure 3C).The total number of deletions in oncocytoma specimens
was 1477 (mean  SD  295  129) (Figure 3C). The
greatest amount of CNV among oncocytoma speci-
mens occurred on chromosome 1: each oncocytoma
sample had CN losses that totaled 49.7%  48.6%
(mean  SD) of the entire length of chromosome 1
(Figure 3C). There were three regions that were amplified
and six regions that were deleted in every oncocytoma
sample (Figure 6). The three amplified regions included
two regions of chromosome 3 comprising a 6.1-kb region
and a 25.8-kb region (both in 3q29). The third common
amplification was 98.9 kb, found on chromosome 22 at
22q13.33. The six deletions consisted of three regions on
chromosome 1, including a 49.6-kb region in 1p31.3, a
70-kb region in 1q25.2, and a 43.5-kb region in 1q44.
Additional CN deletions included a 114.3-kb region in
5q13.2 of chromosome 5, a 14.9-kb region in 10q21.3 of
chromosome 10, and a 9.9-kb region in 13q12.2 of chro-
Figure 3. The location and frequency of CNVs
in samples: chromophobe (A), clear cell (B),
oncocytoma (C), papillary type 1 (D), and pap-
illary type 2 (E). The abscissa is divided into
chromosomes delineated horizontally in line
with the p arm of the chromosome to the left and
the q arm to the right. Copy number gains (am-
plifications; red) are indicated by positive val-
ues. Copy number losses (deletions; blue) are
indicated by negative values, which correspond
to the percentage of samples containing the
CNV. Chromosomes are highlighted yellow if
the average values within each subclassification
contain significant CNVs comprising at least 30%
of the chromosome.mosome 13 (Figure 6).
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amplified segments (mean  SD  201  152) and 1834
deleted segments (mean  SD  306  187) (Table 1;
Figure 3D). The greatest amount of CNV between papil-
lary type 1 samples was found on chromosomes 7, 9, 12,
16, and 17. For each sample, CN gains composed 54.9%
45.4% (mean  SD) of the length of chromosome 17,
46.1%  50.3% of the length of chromosome 7, 35.5% 
39.6% of the length of chromosome 16, and 34.2% 
43.4% of the length of chromosome 12. Copy number
losses totaled 36.5%  45.9% of the length of chromo-
some 9 (Figure 3D). Unlike the other tumor types, no CNV
regions were identified in common to all papillary type 1
samples, although there were 12 regions that were am-
plified and 12 regions that were deleted in five of six
samples.
Papillary type 2 samples had 1418 amplifications
(mean  SD  236  258) and 2790 deletions, yielding,
by far, the highest average number (mean SD 465
522) of CNV events (Table 1 and Figure 3E). The largest
amount of CNV between papillary type 2 samples was
found on chromosomes 7, 19, and 17; each sample had
CN gains that covered 39.0%  42.1% (mean  SD) of
the length of chromosome 7 and 29.4%  41.9% of thelength of chromosome 17. Each sample also had CN
losses that covered 29.6%  29.6% of the length of
chromosome 19 (Figure 3E). In contrast to the papillary
type 1 subtype, there were two regions with CNV dele-
tions common to all six of papillary type 2 samples. These
included a 19.9-kb region on chromosome 9 (9p24.1)
and a 52-kb deletion on chromosome 14 (14q13.2) (Fig-
ure 7).
CNV Analysis by Paired-End Sequencing
Two additional papillary type 2 specimens were obtained
for post hoc SNP array analysis and paired-end genomic
sequencing to validate the presence of deletions identi-
fied on chromosomes 9 (19.9-kb region) and 14 (52-kb
region), in common among all previous papillary type 2
specimens. SNP 6.0 array analysis confirmed the pres-
ence of CNV deletions encompassing and extending be-
yond these regions compared with our reference data-
base of normal samples. Genomic sequencing provided
maps of chromosomes 9 and 14 for both blood and tumor
specimens, achieving an average resolution for each
base call ranging from 3.3 to 5.7 times in these regions.
Figure 4. Chromophobe samples shared four
deleted regions: a 38.7-kb region in 1p21.1 (1:
104066237 to 104104975), a 26.3-kb region in
6q14.1 (6: 77494919 to 77521221), a 208.3-kb
region in 10p12.33 (10: 17792529 to 18000842),
and a 6.8-kb region in 10q22.3 (10: 77924962 to
77931730). Chromophobe samples have three
additional regions that contain CN events in four
of five samples and a region of copy-neutral
LOH in the remaining sample. The three regions
include the following: a 15.6-kb region in
1p36.13 (1: 17119213 to 17134826), a 30-kb re-
gion in 2p16.3 (2: 52612264 o 52638249), and a
17-kb region in 11p15.1 (11: 18901547 to
18918504). The numbers at the top of each lane
are sample ID numbers consistent with Tables 1
and 2. The black window demarcated on each
chromosome (Chr.) indicates the area expanded
to the right. The black window located within
the expanded region indicates the location of a
CNV common to all samples in the tumor type.Areas of CNV in the sequencing data were derived by
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imens with blood samples compiled across each entire
chromosome. The two chromosomal regions containing
deletions common to all papillary type 2 specimens in the
array analysis were identified in these additional speci-
mens via SNP arrays and were verified by genomic se-
quencing of chromosomes 9 and 14 (Figure 8). Not sur-
prisingly, there were differences in the resolution of the
CNV results when SNP array segmentation and paired-
end sequencing were directly compared because of the
high resolution of sequencing technology (single-base
calls versus 680–base marker array spacing between
SNP probes) and direct comparison of tumor to blood
CNV ratios after sequencing versus CNV calculation from
SNP data compared with a pool of normal tissue samples
as a reference database.
Genes Located within Common RCC CNV
Regions
The total number of genes for mRNAs and microRNAs
(miRNAs) encoded within CNV regions ranged from as
few as 190 unique mRNA coding regions and one miRNA
in a papillary type 1 sample (ID number 222) to as many
as 12,542 mRNAs and 348 miRNAs in a single chromo-
phobe sample (ID number 512) (Table 2). We evaluated
the genes contained within common CNV regions for the
overall classification of RCC, as well as associated with a
specific type of tumor (Figure 8). The most commonly
amplified genes among all RCC samples [ie, amplified in
Figure 5. All clear-cell samples shared three deleted regions: a 12.5-kb
region in 3p26.1 (3: 6617676 to 6630163), a 57.1-kb region in 3p23 (3:
32029310 to 32086396), and a 13.7-kb region in 3p21.1 (3: 53000833 to
53014512). The black window demarcated on the chromosome (Chr.) in-
dicates the area expanded to the right. The black window located within the
expanded region indicates the location of a CNV common to all samples in
the tumor type.17 (63%) of the 27 tumor samples] were as follows:
i) rhomboid family member 1 (RHBDF1), ii) DNA-directed
RNA polymerase III subunit K (POLR3K), iii) small nuclear
ribonucleoprotein 25kDa (SNRNP25), and iv) Wiskott Al-
drich Syndrome protein family homolog 1 pseudogene
(LOC100288778). The gene most commonly contained
Figure 6. Oncocytoma samples shared six deleted regions: a 49.6-kb region
in 1p31.3 (1: 62139703 to 62189290), a 70-kb region in 1q25.2 (1: 177623986
to 177693964), a 43.5-kb region in 1q44 (1: 244911496 to 244955034), a
114.3-kb region in 5q13.2 (5: 68892554 to 69006891), a 14.9-kb region in
10q21.3 (10: 66977949 to 66992866), and a 9.9-kb region in 13q12.2 (13:
27526162 to 27536024). There were also three shared amplifications: a 6.1-kb
region in 3q29 (3: 194363224 to 194369329), a 25.8-kb region in 3q29 (3:
196911130 to 196936886), and a 98.9-kb region in 22q13.33 (22: 49482441 to
49581322). The black window demarcated on each chromosome (Chr.)
indicates the area expanded to the right. The black window located within
the expanded region indicates the location of a CNV common to all samples
in the tumor type.
Figure 7. Papillary type 2 samples shared two deleted regions among all
samples: a 19.9-kb region in 9p24.1 (9: 6714105 to 6733969) and a 52-kb
region in 14q13.2 (14: 34360232 to 34412171). The black window demar-
cated on each chromosome (Chr.) indicates the area expanded to the right.
The black window located within the expanded region indicates the loca-
tion of a CNV common to all samples in the tumor type.
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4C (KDM4C), which was deleted in 19 (70%) of 27 sam-
ples. KDM4C is alternatively known as GASC1 or the gene
amplified in squamous cell carcinoma 1 because of its
overexpression in several esophageal squamous cell car-
cinomas.13 KDM4C was the only gene with an altered copy
number state in at least 50% of the samples in each
subtype (Figure 9; see also Supplemental Figure S1 and
Supplemental Table S2 at http://ajp.amjpathol.org).
Genes in CNV Regions Associated with
Subclassification of Renal Tumors
CNV segments shared within an individual tumor classi-
fication were curated for the presence of protein-encod-
ing and miRNA genes. All chromophobe specimens had
eight genes that were entirely lost because of CN dele-
tions, including amylases  1A, 1B, and 1C (AMY1A,
AMY1B, and AMY1C, respectively) on chromosome 1
(Table 3) and the mannose receptor C-type gene
(MRC1), the mannose receptor C-type like gene
(MRC1L1), and family with sequence similarity 23, mem-
ber A (FAM23A), located on chromosome 10 within the
10p12.33 CN deletion. A small part of the signal-trans-
ducing adapter molecule 1 (STAM) gene (7.5%) was also
Figure 8. The rows labeled SEQUENCE and SNP Array indicate copy number
deletions (blue) and amplifications (red) detected in the identical papillary type
2 tumor sample via paired-end genomic sequencing and SNP 6.0 array analysis
(see Materials and Methods for details). The regions depicted correlate with the
locations indicated below each plot on chromosome (Chr.) 9 or 14. The copy
number plot provides copy number calculations for each marker obtained from
the comparison of the SNP data to the reference database of normal samples,
with blank regions indicative of the absence of probes.contained in this chromosome 10 CN deletion, along withthe entire coding region for miRNAs 511–1 and 511–2.
Down-regulation of miR-511-1 has been previously re-
ported in glioblastoma tumors.14 The evaluation of regions
of copy-neutral LOH yielded two additional genes, MAS-
related GPR, member X1 (MRGPRX1), and ciliary rootlet
coiled-coil, rootletin (CROCC), that were contained within
regions affected in 100% of chromophobe samples.
Clear-cell samples had three CNV deletions on chro-
mosome 3 containing 40% of the zinc finger protein 860
(ZNF860) in the 3p23 deletion and 29% of the gene
Scm-like with four mbt domains 1 (SFMBT1) in the 3p21.1
CNV region (Table 3). The SFMBT1 gene shares marked
similarity with the Drosophila Scm (sex comb on midleg)
gene, which encodes a protein containing four malignant
brain tumor repeat (mbt) domains. CNV losses of the
SFMBT1 gene were associated with ventriculomegaly in
elderly persons.15
Oncocytoma samples contained CNV amplifications
comprising the entire miRNA 570 gene (miR-570) and
22% of the mucin 20 gene (MUC20) within the 3q29
region of chromosome 3 (Table 3). MUC20 transcripts
are abundantly expressed in the kidney and up-regulated
in renal tissues of patients with IgA nephropathy.16 An
amplified region on chromosome 22 (22q13.33) con-
tained the complete genes for RAB member of RAS on-
cogene family-like 2B (RABL2B) and acrosin (ACR). Also,
partially contained within this region was part (60%) of the
SH3 and multiple ankyrin repeat domains 3 (SHANK3)
gene, along with three quarters of a ribosomal protein
L23a pseudogene 82 (RPL23AP82). None of the genes in
the chromosome 22 CNV has been implicated in patho-
logical processes. CNV deletions on chromosome 5
(5q13.2) included four members of the general transcrip-
tion factors IIH, polypeptide 2 (GTF2H2) gene/pseudo-
gene family, including GTF2H2, GTF2H2B, GTF2H2C,
and GTF2H2D. These genes are involved in nucleotide
excision repair, and the expression of at least one of
these genes (GTF2H2) has been associated with
chemoresistance in non–small-cell lung cancer cell lines.
Half of the glucuronidase  pseudogene 3 (GUSBP3)
was contained within the 5q13.2 region. Finally, a CNV
deletion on chromosome 13 (13q12.2) contained 10% of
the class III receptor tyrosine kinase FLT3. Ligand bind-
ing to the receptor domain of this kinase activates multi-
ple cytoplasmic effector molecules in pathways involved
in apoptosis, proliferation, and differentiation of hemato-
poietic cells in acute myeloid leukemia.17
Papillary type 2 samples contained a zinc finger pro-
tein (ZNF214) gene, also known as the bromodomain
adjacent to zinc finger domain 1A (BAZ1A), which was
largely contained (85%) within the 14q13.2 CNV deletion
(Table 3). A small component (6%) of the lysine (K)-
specific demethylase 4C gene (KDM4C) was contained
within the 9p24.1 CNV deletion.
Discussion
The use of high-density SNP arrays to interrogate high-
mol.wt. DNA from prototypical renal tumor specimens pro-
vided resolution of CNVs at levels previously unattainable
o the nu
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tion of distinct CNV segments common to each tumor spec-
imen within chromophobe, clear-cell, oncocytoma, or pap-
illary type 2 subtypes. Papillary type 1 specimens were the
only exception among the five RCC subtypes, with no com-
Figure 9. The lists of mRNAs and miRNAs for each subtype were compared
using a Venn diagram. The total number of mRNAs and miRNAs located
within CNV segments in at least 60% of the samples in a subtype are provided
in parentheses, next to the name of the corresponding tumor subtype. The
number contained within the outer circle for a specific subtype indicates
genes found in at least 60% of the samples for that group. Overlapping areas
represent the number of mRNAs or miRNAs found in at least 60% of the
samples of more than one subtype. There was only one gene, KDM4C,
affected by CNV in at least 60% of the samples of all subtypes. (For annota-
tion of individual gene transcripts expressed within each area of overlap,
Table 2. mRNAs and miRNAs Mapped to CNV Segments Detecte
Transcript Database
Group Sample ID no. mRNA amplified
Chromophobe 508 616
509 8920
510 91
511 175
512 2415
Clear cell 513 21
514 722
516 1967
517 45
230 453
Oncocytoma 524 116
525 416
526 152
527 135
221 88
Papillary type 1 528 4174
529 3909
531 4931
222 94
223 1352
224 3763
Papillary type 2 530 35
532 3257
226 1577
227 2215
228 4322
229 2026
Numbers of mRNAs and miRNAs in CNV segments are separated intplease see Supplemental Figure S1 and Supplemental Table S2 at
http://ajp.amjpathol.org).mon CNV regions, despite the presence of many statisti-
cally significant CNV segments within each sample. How-
ever, there were eight regions of CNV gain and nine regions
of CNV loss shared among five of six of these specimens.
Shared RCC type-specific copy number changes included
many previously undetected noncoding segments (ie, DNA
not targeted for translation into protein products, suggesting
a potentially important role for intronic and intergenic DNA in
tumorigenesis). Although each tumor subclassification
contained a different set of common chromosomal re-
gions with copy number alterations specific to that phe-
notype, there was overlap among the five RCC catego-
ries, depending on the size and location selected (eg, a
100-megabase segment on chromosome 7 was present
in 20 of 27 specimens).
The tumor specimens in this study derived from pa-
tients presenting with sporadic RCC and were classified
and selected by a panel of pathologists as illustrative
samples of their diagnostic classification. The copy num-
ber analysis revealed genomic regions near or overlap-
ping regions associated with hereditary RCCs that were
often affected in these sporadic tumors. Of the 27 spo-
radic renal neoplasms analyzed in this study, seven sam-
ples (three chromophobes, one clear cell, one papillary
type 1, and two papillary type 2) exhibited a copy number
decrement overlapping the BHD gene, which exhibits
hereditary allelic loss in chromophobe, papillary, and
clear-cell renal cancers.18 Copy number losses in the
VHL gene typical of inherited clear-cell cancer occurred
in nine of the 27 tumors (two chromophobe, four clear
ch Tumor Sample Using the NCBI Reference Sequence
mRNA deleted miRNA amplified miRNA deleted
3467 28 125
3169 258 73
124 1 4
124 1 2
10,127 51 297
2073 0 40
714 17 24
3311 48 131
7886 0 193
646 22 14
183 1 4
3398 10 77
1021 4 16
2428 3 97
3168 1 113
1471 99 31
309 93 9
2368 115 109
96 1 0
1774 27 101
4773 142 124
165 0 4
6226 93 171
1269 46 73
4873 106 148
2206 115 47
1492 58 55
mber amplified and the number deleted.d in Eacell, and three papillary type 2), whereas amplification of
ocated
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illary RCC occurred in eight of the 27 tumors (two chro-
mophobe, three papillary type 1, and three papillary type
2). Five specimens had copy number deletions (two chro-
mophobe, one clear cell, and two oncocytoma), and one
papillary type 1 specimen exhibited amplification of the
fumarate hydratase gene, which exhibits germline muta-
tions in renal carcinomas. These data indicated that DNA
domains typically associated with inherited RCC were
also unstable genomic regions susceptible to changes in
sporadic renal cancers. Because these CNV alterations
often occurred across vastly different phenotypes of spo-
radic cancers, it was likely that they represented passen-
ger, rather than driver, mutations. However, these results
emphasized the need for mechanistic studies of inherited
DNA alterations regarding their impact on the phenotype
of hereditary cancers to understand their contribution as
genetic determinants of tumorigenesis.
Deletions in the short arm of chromosome 3 and am-
plifications in the long arm of chromosome 5 were pres-
ent in clear-cell tumors, consistent with prior cytogenetic
studies19 of sporadic clear-cell carcinoma. Extensive
loss of chromosome 3p, including the VHL gene, was
observed in 80% of the clear-cell tumors, in agreement
with reports9,20 that 82% of clear-cell tumors harbor a
VHL mutation. The clear-cell sample that did not have a
CN loss of the VHL gene or any large segments of 3p had
the greatest amount of overall CNV across the entire
genome (38%), compared with the other clear-cell sam-
ples. One of the three regions of copy number loss com-
mon to all clear-cell samples was a 13.7-kb region of
chromosome 3 at 3p21.1. Recently, a histone methyl-
transferase gene, SETD2/HypB, was identified in this re-
gion as a prospective tumor suppressor gene.21,22 In the
Table 3. Genes Located Within CNV Segments in 100% of the Sa
Group Cytoband
Region
length CN status
Chromophobe 1p21.1 38,738 Deletion
1p36.13 15,613 Deletion, LOH
2p16.3 25,985 Deletion, LOH
6q14.1 26,302 Deletion
10p12.33 208,313 Deletion
10q22.3 6768 Deletion
11p15.1 16,957 Amplification, LOH
Clear cell 3p26.1 12,487 Deletion
3p23 57,086 Deletion
3p21.1 13,679 Deletion
Oncocytoma 1p31.3 49,587 Deletion
1q25.2 69,978 Deletion
1q44 43,538 Deletion
3q29 6105 Amplification
3q29 25,756 Amplification
5q13.2 114,337 Deletion
10q21.3 14,917 Deletion
13q12.2 9862 Deletion
22q13.33 98,881 Amplification
Papillary
type 2
9p24.1 19,864 Deletion
14q13.2 51,939 Deletion
*The percentages in parentheses represent the amount of the gene lpresent study, 80% of the clear-cell tumors had a loss ofthe SETD2 gene, whereas all specimens had a loss of the
SFMBT1 gene at 3p21. Both of these gene products
interact with histone H3 (ie, SFMBT1 binds monomethy-
lated and dimethylated forms of H3K9, inducing tran-
scriptional repression, and SETD2 is responsible for trim-
ethylation of H3K36, associated with active/permissive
chromatin).23,24 We can only speculate on the interactive
effect of losing both SFMBT and SETD2, but these data
suggest that histone modifications play an important role
in clear-cell RCC. Furthermore, this paradigm may apply
broadly to renal neoplasms because KDM4C, a lysine
demethylase that modifies both H3K9 and H3K36, was
affected in 60% of the RCC specimens analyzed in this
study.25
Chromophobe RCCs typically have copy number dec-
rements in chromosomes 1, 2, 6, 10, 13, 17, and/or 21.26
This broad genomic instability was reflected among the
chromophobe specimens in this study, with the added
observation that chromosome 19 contained copy number
losses affecting many (60%) of the chromophobe spec-
imens. Gene mutations specific to chromophobe tumors
are yet to be identified, and the regions of CNV common
to chromophobe tumors in this study represented pro-
spective target areas for further investigation. In particu-
lar, the 208.3-kb deletion at 10p12.33 was interesting
because it contained both the STAM gene, which has a
role in MYC induction, and the miRNA 511-1/2 gene,
which has been associated with adrenocortical tumor
formation.27
Papillary renal cell tumors are characterized by gains
within two or more chromosomes from among chromo-
somes 7, 8, 12, 16, 17, and 20 and the long arm of
chromosome 3, without 3p loss.19 We identified amplifi-
cations in both papillary type 1 and 2 tumors on chromo-
Genes within the region*
A (100%), AMY1B (100%), AMY1C (100%)
C (27%)
(7.5%), FAM23A (100%), MRC1 (100%), MRC1L1 (100%),
511-1 (100%), MIR511-2 (100%)
RX1 (100%)
0 (40%)
T1 (29%)
(12%)
DH (2%)
0 (100%), MUC20 (22%)
2 (98%), GTF2H2B (98%), GTF2H2C (98%), GTF2H2D
), GUSBP3 (50%)
(10%)
2B (100%), SHANK3 (62%), ACR (100%), RPL23AP82 (77%)
C (6%)
(85%)
in the CNV region. Noncoding regions are blank.mples
AMY1
CROC
STAM
MIR
MRGP
ZNF86
SFMB
INADL
SCCP
MIR57
GTF2H
(98%
FLT3
RABL
KDM4
BAZ1Asomes 7 and 17, but only papillary type 1 tumors showed
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imens exhibited two common regions of copy number
loss that contained KDM4C and BAZ1A, which play a role
in nuclear receptor–mediated transcription repression.
Papillary type 1 specimens had losses on chromosome 9
that were not observed in papillary type 2 specimens,
whereas the latter had losses on chromosome 19 that
were not observed in type 1 specimens. Papillary type 1
samples contained no CNV regions common to each
sample, but there were overlapping CNV regions found in
five of six specimens. Twelve genes were contained in
these regions, including significantly reduced copy num-
bers for CDC14B (cell decision cycle 14 homologue B),
an essential regulator of the G2 DNA damage checkpoint,
and HABP4 (hyaluronic binding protein 4), involved in
remodeling of chromatin and transcriptional regulation
(GeneCards V3, http://www.genecards.org, last ac-
cessed January 6, 2012). Common (five of six) papillary
type 1 copy number gains composed BCAS3 (breast
carcinoma–amplified sequence 3), expressed in breast
and brain neoplastic tissue and implicated in chronic
kidney disease; WWOX (WW domain–containing oxi-
doreductase), a tumor suppressor that functions syner-
gistically with p53 in breast, prostate, and ovarian can-
cers; and TBX2 (T-box transcription factor 2), which
has enhanced cell proliferation in multiple cancers,
including melanoma, breast, pancreatic, and lung tu-
mors (GeneCards V3, http://www.genecards.org, last
accessed January 6, 2012).28–31
Renal oncocytoma specimens contained CNVs within
chromosomes 1 and 14, with chromosome 1 exhibiting
the most variation, as previously reported.32 Nine CNV
regions were common to all oncocytoma specimens, in-
dicating a high degree of shared genomic instability in
these benign neoplasms, similar to that observed within
the chromophobe classification. Important tumor-related
genes in these regions included MUC20 as part of the
MET/GRB2-RAS pathway, GTFH2 transcription factors in-
volved in nucleotide excision repair, and the FLT3 gene,
which incorporates the most frequently identified mutations
associated with acute myeloid and acute lymphoblastic leu-
kemia (GeneCards V3, http://www.genecards.org, last ac-
cessed January 6, 2012).33 Many of the CNV regions iden-
tified in oncocytomas were also present in chromophobe
samples, making it difficult to classify these two subtypes
using these nine shared regions exclusively. The overlap in
genotypic variations between these classifications was con-
sistent with the historical observation that oncocytomas
were sometimes difficult to distinguish from chromophobe
specimens on a histological basis. However, multiple
unique DNA domains specific to each subclassification
were revealed using the high-density SNP arrays, and these
segments contributed additional molecular indicators to
help distinguish between these tumor types and potentially
shed light on their different clinical behaviors.32
The present study revealed substantially more CNV
segments than previous SNP studies of RCC (eg, 250K
Affymetrix arrays detected an average of 5.8 amplifica-
tions and 6.8 deletions in clear-cell tumors, whereas we
found an average of 73 distinct amplifications and 160
independent deletions).34 These differences were attrib-utable to implementation of the SNP 6.0 platform and
several quality control measures used in our study, in-
cluding the following: i) use of high-integrity genomic
DNA from flash-frozen specimens acquired with minimal
warm ischemic time, ii) acquisition of precisely curated
RCC specimens classified into distinct tumor pheno-
types, and iii) statistical comparison with a group of nor-
mal tissues (n  31) acquired and processed in our
laboratory on the same platform following identical quality
control standards. These measures resulted in detection
of statistically significant tumor-specific CNV in segments
as small as 2.9 kb in small tumor sample groups. The
enhanced resolution allowed us to extend earlier findings
regarding genes associated with renal cancers to poten-
tially important new segments, including noncoding re-
gions, such as the 12.5-kb deletion at 3p26.1 in clear-cell
samples. The data also suggest that noncoding DNA
regions may contribute to tumorigenesis through altera-
tions in chromatin structure or transcriptional regulation.
We were able to confirm our findings, in part, by
genomic sequencing of additional papillary type 2 spec-
imens, extending the results obtained by SNP array anal-
ysis. However, the higher acuity provided by fine map-
ping of regions identified using global SNP assays will
likely reveal local differences among samples in the mag-
nitude and specific locations of the copy number
changes and the presence of other DNA modifications.
Consequently, it is likely that SNP arrays represent a
potentially important screening method for identifying
genomic hot spots that may serve as biomarkers useful
for the detection of RCC and the identification of renal
tumor subclassifications. However, direct genomic se-
quencing efforts will be required to elaborate the range
and specific types of changes that occur within these
segments and the precise mechanisms by which these
regions and other protein-coding regions subserve the pro-
cess of tumorigenesis.
The finding that four of five subclassifications of renal
neoplasms shared common CNVs was unexpected given
the prevailing theory that cancers arise from disparate
genomic changes that induce tumorigenesis through
convergence on common pathways. Although the overall
results of this study confirm the widespread occurrence
of tumor-related DNA rearrangements, the subset of
shared genomic amplifications or deletions that we iden-
tified in each renal tumor subclassification could provide
critical diagnostic or prognostic biomarkers of RCCs. Our
results support the need for large-scale studies of high-
quality RCC specimens using high-density SNP arrays
and/or targeted sequencing of the tumor type–specific
regions delineated in this study to determine their diag-
nostic efficacy and provide further insight into their role in
renal cell tumorigenesis.
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